1. (Four Times Amended) An immunogenic composition consisting essentially of an adjuvant and an antigen joined together;

[wherein said adjuvant and said antigen are joined together;]

wherein said adjuvant is selected from the group consisting of an antibody that binds cell surface receptor CD40, a part of said antibody that is effective at binding CD40, and a CD40 ligand; and

wherein when said adjuvant binds to CD40 of a B-lymphocyte cell said adjuvant helps in activating said B-lymphocyte cell.

2. (Three times Amended) A vaccine consisting essentially of an adjuvant and an antigen joined together;

wherein said adjuvant is selected from the group consisting of an antibody that binds cell surface receptor CD40, a part of said antibody that is effective at binding CD40, and a CD40 ligand;

wherein when said adjuvant binds to CD40 of a B-lymphocyte cell said adjuvant helps in activating said B-lymphocyte cell; and

wherein the vaccine promotes Ig secretion and isotype switching.

25. (Amended) A vaccine comprising an adjuvant and an antigen that are joined together; wherein said adjuvant is selected from the group consisting of an antibody that binds cell surface receptor CD40, a part of said antibody that is effective at binding CD40, and a CD40 ligand;

wherein when said adjuvant binds to CD40 of a B-lymphocyte cell said adjuvant helps in activating said B-lymphocyte cell;

wherein the vaccine promotes Ig secretion and isotype switching; and wherein the vaccine does not comprise an exogenous cytokine.

